Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique
Biologie Aujourd’hui, 215 1-2 (2021) 25-43
Published online: 2021-08-16
Articles citing this article
The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
Cited article:
This article has been cited by the following article(s):
Advances in MLKL-targeted inhibitors and PROTACs for necroptosis therapeutics
Pengcheng Dai, Yufeng Xin, Xiuting Qin, Hao Ma and Chunlin ZhuangBioorganic & Medicinal Chemistry 128 118246 (2025)
https://doi.org/10.1016/j.bmc.2025.118246
Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development
Yiting He, Tianzuo Liao, Xuan'er Wang, Qian Xiao, Hongmei Wang, Rui He, Chenyu Zhao, Xinmiao Tian, Qinghua Gao and Liying HaoBioorganic Chemistry 164 108846 (2025)
https://doi.org/10.1016/j.bioorg.2025.108846
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment
Md Sadique Hussain, Liming Zhang, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Yumna Khan, Vikas Jakhmola, Ali Hanbashi, Wedad Mawkili and Gyas KhanFuture Medicinal Chemistry 17 (14) 1725 (2025)
https://doi.org/10.1080/17568919.2025.2533113
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang and Chunchu DengMolecular Neurobiology 62 (8) 9686 (2025)
https://doi.org/10.1007/s12035-025-04838-0
COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies
Michèle Reboud-Ravaux and Chahrazade El AmriFrontiers in Drug Discovery 2 (2022)
https://doi.org/10.3389/fddsv.2022.892057
Le protéasome, la seconde vie d’une cible thérapeutique validée : aspects structuraux et nouveaux inhibiteurs
Michèle Reboud-RavauxBiologie Aujourd’hui 215 (1-2) 1 (2021)
https://doi.org/10.1051/jbio/2021005